Brain cancer is successfully treated with Car-T cells, GILEAD said

brain cancer departs from the treatment of Gilead Sciences. Treatment is carried out by the own patients with patients. The tumors disappeared in 62% of patients with recurrent glioblastoma.

The study presented at the meeting of the American Clinical Oncology Society in Chicago is the last of several studies on the testing of a new generation of «T-cells with chimeric antigenic receptors. These are also called CAR-T, writes XRUST. This is immunotherapy in which patients of patients are configured to recognize and destroy cancer cells.

The work of researchers from the Pennsylvania University and Gilead was devoted to testing Car-T double therapy in order to overcome the protective mechanisms of glioblastoma-the most common tumor of the brain in adults.

A similar method is already used to treat blood cancer, including leukemia, including leukemia, including leukemia, including leukemia Lymphoma and multiple myeloma, and such treatment usually affects only one target in the tumor.

However, solid tumors, such as glioblastoma, as a rule, have several subpopulations of tumor cells, which suggests that the success of the treatment will require more than one goal, the researcher from the Pennsylvania University.

for the treatment, the team chose a protein. EGFR, which is found in 50-60 % of all tumors of glioblastoma, and interleukin-13 alpha 2, which is present in 75 % of glyoblastoma tumors.

Work with several proteins was started after the treatment of patients with advanced glitor, in which the cancer recovits after the treatment initial treatment with surgical means, radiation therapy and chemotherapy. Such patients live for no more than 10 months.

The use of a new technique made it possible to reduce neglected tumors by 62% in eight of 18 patients. The rest of the tumor disappeared.

Xrust brain cancer is successfully treated with Car-T cells, GILEAD said